Astrazeneca earnings were $10.4B for the trailing 12 months ending Jun 30, 2026, with 26% growth year over year. The latest AZN earnings report on Jun 30, 2026 announced Q2 2026 earnings of $2.5B, down 18.6% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, AZN reported annual earnings of $10.2B, with 45.3% growth. The next AZN earnings date is Nov 5, 2026.
AZN past earnings growth
How has AZN's earnings growth performed historically?
On AZN's earnings call on Jul 27, 2026, Astrazeneca (NYSE: AZN) reported Q2 2026 earnings per share (EPS) of $1.61, up 1.9% year over year. Total AZN earnings for the quarter were $2.51 billion. In the same quarter last year, Astrazeneca's earnings per share (EPS) was $1.58.
The next AZN earnings date is Nov 5, 2026. Add AZN to your watchlist to be reminded of Astrazeneca's next earnings date.
Is Astrazeneca profitable or losing money?
As of the last Astrazeneca earnings report, Astrazeneca is currently profitable. Astrazeneca's net profit (also called net income) for the twelve months ending Jun 30, 2026 was $10.45 billion, a 25.93% increase year over year.
What was AZN's earnings growth in the past year?
As of Astrazeneca's earnings date in Jul 27, 2026, Astrazeneca's earnings has grown 25.98% year over year. This is 1.81 percentage points lower than the US Drug Manufacturers - General industry earnings growth rate of 27.79%. AZN earnings in the past year totalled $10.45 billion.
What are Astrazeneca's earnings expectations?
The current EPS estimate for Astrazeneca's earnings report in Nov 5, 2026 is $2.17.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.